Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer

BACKGROUND: Trastuzumab has been prevailingly accepted as a beneficial treatment for gastric cancer (GC) by targeting human epidermal growth factor receptor 2 (HER2)-positive. However, the therapeutic resistance of trastuzumab remains a major obstacle, restricting the therapeutic efficacy. Therefore...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:World J Surg Oncol
Autors principals: Yu, Chaoran, Xue, Pei, Zhang, Luyang, Pan, Ruijun, Cai, Zhenhao, He, Zirui, Sun, Jing, Zheng, Minhua
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6106878/
https://ncbi.nlm.nih.gov/pubmed/30134903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12957-018-1475-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars